Clinical Trials

First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics' novel GMI-1359 drug candidate in patients with advanced breast cancer.

Vasopharm completes patient enrollment for phase 3 traumatic brain injury trial (NOSTRA)

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.

Incyte announces that TRuE-AD2 trial of ruxolitinib cream met its primary endpoint in patients with atopic dermatitis

Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥ 12 years) with atopic dermatitis (AD).

Acceleron’s Sotatercept achieved primary and secondary endpoints in PULSAR trial in pulmonary arterial hypertension

Acceleron Pharma said that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH).

DS-8201 meets primary endpoint in phase 2 DESTINY-Gastric01 trial

Daiichi Sankyo and AstraZeneca said that the HER2 directed antibody drug conjugate (ADC) DS-8201 has met the primary endpoint in the phase 2 DESTINY-Gastric01 trial.

Lexicon Pharmaceuticals announces real-world data on telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome

Lexicon Pharmaceuticals announced real-world data on XERMELO’s (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium.

Roche’s Tecentriq fails to meet primary endpoint in MIUC trial

Roche’s Tecentriq (atezolizumab) has failed to meet its primary endpoint in phase III muscle-invasive urothelial cancer (MIUC) trail.

LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia

LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial.

Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial

Roche announced that its risdiplam has achieved primary endpoint in the FIREFISH study in infants with type 1 spinal muscular atrophy.